CoChat

Randomized Trial of Sertraline Versus Venlafaxine XR in Major Depression: Efficacy and Discontinuation Symptoms

Open access
Sir, Aytekin, D'Souza, Russell F., Uguz, Sukru, George, Tom, Vahip, Simavi, Hopwood, Malcolm, Martin, Andrew J., Lam, William, Burt, Tal · 2005 · The Journal of Clinical Psychiatry

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Abstract

BACKGROUND: The comparative efficacy of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) was recently debated. Meta-analyses, based mainly on fluoxetine comparator data, suggest that the SNRI venlafaxine has superior efficacy to SSRIs in treatment of major depression. OBJECTIVE: To compare quality of life (QOL), efficacy, safety, and tolerability associated with sertraline and venlafaxine extended release (XR) for treatment of DSM-IV major depression. METHOD: This was an 8-week, double-blind, randomized study of sertraline (50-150 mg/day) versus venlafaxine XR (75-225 mg/day), followed by a 2-week taper period. Subjects were recruited from 7 sites in Turkey and 6 sites in Australia between October 2002 and July 2003. The primary outcome measure was the Quality of Life Enjoyment and Satisfaction Questionnaire. Secondary outcome measures included measures of depression (including response and remission), anxiety, pain, safety (e.g., blood pressure), and tolerability (e.g., discontinuation symptoms). RESULTS: A total of 163 subjects received study treatment (women, 69%; mean age, 37.0 [SD = 12.9] years). No significant differences in QOL or efficacy were noted between treatments on the primary or secondary endpoints for the total study population or the anxious depression and severe depression subgroups. A priori analyses of symptoms associated with treatment discontinuation demonstrated no difference between treatment groups. However, in post hoc analyses, sertraline was associated with less burden of moderate to severe discontinuation symptoms. Venlafaxine XR was associated with a relative increase in mean blood pressure (supine diastolic blood pressure, -4.4 mm Hg difference at week 8/last observation carried forward). CONCLUSION: Sertraline and venlafaxine XR demonstrated comparable effects on QOL and efficacy in treatment of major depression, although sertraline may be associated with a lower symptom burden during treatment discontinuation and a reduced risk of blood pressure increase.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4088/jcp.v66n1015

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Research works printed but not linked: 2

  1. [14]14. Russell JM, Koran LM, Rush J, et al. Effect of concurrent anxiety on response to sertraline and imipramine in patients with chronic depression. Depress Anxiety 2001;13:18-27
  2. [16]16. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 2000

Cited by

See all 130

Metadata

Authors
Sir, A., D'Souza, R. F., Uguz, S., George, T., Vahip, S., Hopwood, M., Martin, A. J., Lam, W., & Burt, T.
Venue
The Journal of Clinical Psychiatry
Published
2005-10-15
Volume
66
Issue
10
Pages
1312-1320
ISSN
0160-6689 (ISSN-L)
OpenAlex
W2172129050
Cited by
129
References
24
Citations by year
2026: 1 · 2025: 3 · 2024: 4 · 2023: 2 · 2022: 6 · 2021: 5 · 2020: 4 · 2019: 6 · 2018: 8 · 2017: 2 · 2016: 2 · 2015: 7 · 2014: 10 · 2013: 5 · 2012: 3
FWCI
6.80
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • The Journal of Clinical Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
  • DukeSpace (Duke University) (submittedVersion, cc-by-nc-nd)
  • Çukurova University Institutional Repository (submittedVersion)
Funders
  • Pfizer
  • Pfizer Australia
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Social Sciences › Psychology › Clinical Psychology › Psychological Treatments and Disorders
Keywords
sertraline, venlafaxine extended release, major depressive disorder, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, quality of life, blood pressure, drug tolerability, severe depression
MeSH terms
Venlafaxine Hydrochloride, Adult, Ambulatory Care, Blood Pressure, Cyclohexanols, Delayed-Action Preparations, Major Depressive Disorder, Double-Blind Method, Female, Health Status, Humans, Male, Psychiatric Status Rating Scales, Quality of Life, Severity of Illness Index, Substance Withdrawal Syndrome, Treatment Outcome, Selective Serotonin Reuptake Inhibitors, Sertraline

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Randomized Trial of Sertraline Versus Venlafaxine XR in Major Depression: Efficacy and Discontinuation Symptoms. https://app.cochat.ai/papers/10.4088/jcp.v66n1015
The paper
Sir, A., D'Souza, R. F., Uguz, S., George, T., Vahip, S., Hopwood, M., Martin, A. J., Lam, W., & Burt, T. (2005). Randomized Trial of Sertraline Versus Venlafaxine XR in Major Depression: Efficacy and Discontinuation Symptoms. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.v66n1015

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.